Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression
View abstract on PubMed
Summary
This summary is machine-generated.Alveolar rhabdomyosarcoma (aRMS) growth is driven by the PAX3-FOXO1 oncogene, which upregulates RASSF4. RASSF4 inhibits the MST1 tumor suppressor, promoting cell cycle progression and tumor development in aRMS.
Area Of Science
- Oncology
- Molecular Biology
- Cell Biology
Background
- Alveolar rhabdomyosarcoma (aRMS) is an aggressive skeletal muscle sarcoma.
- The PAX3-FOXO1 fusion oncogene drives aRMS development but its mechanisms are unclear.
- Previous work showed PAX3-FOXO1 enables bypass of cellular senescence checkpoints.
Purpose Of The Study
- To investigate the mechanisms by which PAX3-FOXO1 drives aRMS initiation and progression.
- To identify downstream targets of PAX3-FOXO1 involved in senescence evasion.
- To explore the role of the Hippo pathway in aRMS pathogenesis.
Main Methods
- Analysis of RASSF4 expression in aRMS cell lines and tumors.
- Investigating the effect of enhanced RASSF4 expression on cell cycle progression and senescence.
- Assessing the impact of RASSF4 on the Hippo pathway components MST1 and YAP.
- Correlating YAP expression with RMS tumor status.
Main Results
- PAX3-FOXO1 upregulates RASSF4 expression in aRMS.
- RASSF4 promotes cell cycle progression and senescence evasion.
- RASSF4 inhibits the Hippo pathway tumor suppressor MST1.
- The downstream Hippo pathway target YAP is upregulated in RMS tumors.
- PAX3-FOXO1-mediated MST1 inhibition promotes aRMS tumorigenesis.
Conclusions
- Hippo pathway dysfunction contributes to aRMS development.
- RASSF4 plays a progrowth role in aRMS by suppressing MST1 signaling.
- PAX3-FOXO1 utilizes RASSF4 to inhibit MST1 and promote aRMS tumorigenesis.